Essentials• Apixaban is a novel oral anticoagulant that has not been studied in pregnant
patients.• Our objective was to determine the rate and extent of the placental transfer of …

Although currently available anticoagulants are effective for the prevention and treatment of
thromboembolic disorders, they have several drawbacks. Low molecular weight heparin and …

We described the development and full validation of a rapid, high throughput sensible and
accurate LC method using tandem mass spectrometry detection for determining apixaban …

The new oral anticoagulants may prove to be one of the most significant innovations in
clinical practice in the past 60 years. Apixaban and rivaroxaban are specific inhibitors of …

Background: Apixaban is an oral, direct factor Xa (FXa) inhibitor in late-stage clinical
development. This study assessed effects of the direct FXa inhibitors, apixaban and …

Anticoagulation is the most-important intervention to prevent stroke in patients with atrial
fibrillation (AF). Despite a lower point prevalence of AF in Asian communities and Asian …

Apixaban is an oral, direct and highly selective factor Xa (FXa) inhibitor in late-stage clinical
development. This study evaluated the in vitro effect of apixaban on human platelet …

It was the objective of this study to systematically compare the effects of apixaban versus
enoxaparin in patients following total knee arthroplasty (TKA). A systematic search of …

The direct thrombin inhibitor, dabigatran, as well as the direct factor Xa inhibtors
rivaroxaban, apixaban, and edoxaban, display pharmacodynamic features quite similar to …

Purpose The pharmacology, pharmacokinetics, efficacy, and safety of apixaban are
reviewed. Summary Apixaban is an oral, direct, selective factor Xa inhibitor with a rapid …